Expertise: Cell & Gene Therapy 38 results

Cell & Gene Therapy

Navigating Cell Therapy Development: The benefits of working with a Clinical CRO – CDMO Partnership

Cell therapies, despite their transformative potential, face significant barriers that can hinder their development and commercialization. Safety concerns, manufacturing challenges, analytical complexities and scale-up difficulties present substantial risks. Competition from other drug modalities, coupled with the inherent complexity of clinical development, further complicates the pathway to market. Distribution and supply chain challenges add another layer…

Cell & Gene Therapy

Early Cell Therapy Development: Navigating the Journey to First-In-Human Studies

Cell therapy development faces significant challenges on the path from concept to clinical application. From navigating the regulatory landscape to ensuring product consistency and standardization, the initial phases of developing cell therapies require careful planning and close collaboration among cross-functional teams. In this blog, we explore the complexities of early cell therapy development, with a…

Cell & Gene Therapy

FDA INTERACT Meetings: Early Interactions for Cell and Gene Therapy Sponsors

Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. These therapies frequently target diseases in patients that are rare (affecting fewer than 200,000…

Consulting

3 Characteristics of a Successful Cell and Gene Therapy Nonclinical Program

Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. The Cell and Gene Therapy (CGT) field has unprecedented potential to effectively treat and/or cure genetic-based rare and orphan diseases and expand the reach of personalized medicine. This blog will…

Consulting

Design Considerations in Nonclinical Development of Cell and Gene Therapies

Designing an adequate nonclinical program to support the safety of cell or gene therapy products is not always straightforward. In this blog, we will address common questions we receive from our clients and aspects to consider when designing those nonclinical studies.  In which species should the toxicity study be conducted? Does it have to be…